1. P-059SM-88 therapy in high-risk poor prognosis pancreatic cancer (PDAC). (2nd July 2019) Authors: Noel, M; Wang-Gillam, A; Ocean, A; Chawla, S; Chung, V; DelPriore, G; Picozzi, V Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P-155Open-label, multicenter, single-arm study of FABLOx (metronomic 5-fluorouracil plus nab-paclitaxel, bevacizumab, leucovorin, and oxaliplatin) in patients with metastatic pancreatic cancer: Phase I results. (20th June 2018) Authors: Sahai, V; Saif, W; Kalyan, A; Philip, P; Rocha-Lima, C; Ocean, A; Ondovik, M; Simeone, D; Karnoub, M; Louis, C; Picozzi, V Journal: Annals of oncology Issue: Volume 29(2018)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P-260PANOVA-3: A phase 3 study of tumor treating fields with nab-paclitaxel and gemcitabine for front-line treatment of locally advanced pancreatic adenocarcinoma (LAPC). (2nd July 2019) Authors: Picozzi, V; Weinberg, U; Giladi, M; Bomzon, Z; Kirson, E Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P-266Metastatic pancreatic cancer: Characteristics of long-term survivors. (2nd July 2019) Authors: Mandelson, M; Picozzi, V Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗